NFL Biosciences: Activities & Results for the 1st half of 2022 – 2022-10-25 at 07:00
The Phase II/III clinical study of drug candidate NFL-101 for smoking cessation continues with the participation of 8 clinical centers in France
Extension of intellectual property with the registration of an NFL Biosciences patent in China and South Korea
Partnership with Themis Medicare for the development of NFL-101 in India
Partnership with Athena Pharmaceuticals for the global development of NFL-301
Recruitment of a Financial Director
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company that develops botanical drugs for the treatment of dependencies and addictions, presents its results for the first half of 2022 approved by the Board of Directors on October 24, 2022. Financial statements accounts ended June 30, 2022 were subject to a limited review by the Company’s Statutory Auditors. On this occasion, NFL Biosciences, listed on the stock market in July 2021, returns in particular to the advances in the development of NFL-101, its drug candidate for smoking cessation.
The Phase II/III clinical study of NFL-101 continues with the participation of 8 clinical centers in France
